07.20.22
Rank: #16 (Last year: #17)
$8.20 Billion
Prior Fiscal: $6.76 Billion
Percentage Change: +21.3%
R&D Expenditure: $557M
Best FY21 Quarter: Q4 $2.13B
Latest Quarter: Q1 $2.17B
No. of Employees: 24,389
Global Headquarters: Geneva, Switzerland
KEY EXECUTIVES:
David J. Endicott, CEO
Tim Stonesifer, CFO
Franck Leveiller, SVP, Head Global R&D
Heather Attra, SVP, Global Head Quality and Regulatory Affairs
Ian Bell, President, Global Business & Innovation
Jeanette Bankes, President & GM, Global Surgical Franchise
Andy Pawson, President & GM, Global Vision Care Franchise
In November, eye care firm Alcon celebrated the near-end of its third year as a standalone business by proclaiming its intention to acquire Ivantis, developer and manufacturer of the novel minimally-invasive glaucoma surgery (MIGS) device, the Hydrus Microstent. Designed to reduce intraocular pressure in open-angle glaucoma patients in connection with cataract surgery, Ivantis launched Hydrus in the U.S. and it’s also currently approved and marketed in the U.K., Germany, Canada, Australia, and Singapore.
The microstent is implanted into the Schlemm’s canal to boost outflow, reducing eye pressure to treat mild to moderate glaucoma. The company highlighted that a five-year Horizon clinical study showed 65% of Hydrus patients remained medication-free at five years post-implant, with 60% reduction in risk of invasive secondary glaucoma surgeries compared to cataract surgery alone.
“Glaucoma is the second-largest cause of blindness after cataracts, impacting more than 75 million people globally, with significant unmet patient need. This transaction will allow us to add a uniquely effective product into our glaucoma portfolio around the world,” Alcon CEO David Endicott told the press when the $475 million deal was announced. “Our global commercial footprint and development capabilities make us well positioned to build on the success of Ivantis and help even more patients see brilliantly with Hydrus Microstent.”
The deal for Ivantis was completed at the beginning of this year. Alcon plans to pursue further standalone surgery indications for Hydrus in the U.S., with clinical trials underway.
In 2021, Alcon’s net sales rebounded from COVID-19, which stifled many medical device market sectors. The firm posted $8.2 billion in revenue, rising about 21% over the year prior. The growth was driven mainly by landmark product launches as well as strong commercial execution and underpinned by global markets recovering from COVID-19, according to the company’s annual report.
Sales in the U.S. captured 44% of Alcon’s revenue with $3.7 billion posted. International sales reached $4.6 billion last year, making up the remaining 56%.
The surgical franchise contributed $4.7 billion to sales, rising an impressive 27% over the prior year that was impacted by the COVID-19 pandemic. Within the business, implantables proceeds grew 35% to $1.52 billion due to market improvements and the ongoing adoption of advanced technology intraocular lenses (IOLs), which included the rollout of Vivity and continued demand for PanOptix.
Consumables revenue increased 15% to $2.39 billion primarily due to market improvements over the prior year. Equipment/other sales rose 25% to $793 million, driven by demand for cataract and refractive equipment as well as other refractive products.
The surgical business’s one major product launch came in the U.S. last January with the AcrySoft IQ Vivity, a non-diffractive extended depth of focus IOL to mitigate presbyopia for patients undergoing cataract surgery. The first-of-its-kind IOL—approved by the FDA in February 2020—stretches and shifts light without splitting it, delivering monofocal-quality distance with “excellent” intermediate and functional near vision. Vivity is also available in toric designs and bolsters Alcon’s portfolio of presbyopia-mitigating IOLs.
The vision care business accrued $3.52 billion, growing 15% over the previous year, which was affected by COVID-19. Contact lenses sales grew 16% with $2.14 billion, due to strong U.S. recovery and growth in silicone hydrogel contact lenses including Precision1, Precision1 for Astigmatism, and Dailies Total1. Ocular health sales expanded 14% to $1.38 billion as a result of the Pataday Extra strength launch, and sales of Simbrinza after the firm’s acquisition of the U.S. commercialization rights.
The franchise began last year with the U.S. launch of Precision1 for Astigmatism contact lenses in January. The daily disposable, silicone hydrogel contact lens designed for astigmatic patients was born from the firm’s Water Gradient Technology and features SmartSurface, a permanent, micro-thin layer of moisture that steps up from 51% water at the core to over 80% water at the outer surface, according to Alcon data. This supports a stable tear film for lasting performance.
The exclusive U.S. rights from Novartis to sell the Simbrinza ophthalmic eye drops were gained last April. The drops are used to reduce elevated intraocular pressure for open-angle glaucoma or ocular hypertension patients. Combined with Alcon’s existing over-the-counter eye drops, adding Simbrinza makes for a bolstered ophthalmic eye drop portfolio.
That same day Alcon launched its Systane hydration multi-dose, preservative-free lubricant eye drops for sensitive dry eyes. The new option helps patients with aqueous deficient dry eye, protecting against further irritation and relieving dryness. Systane complete preservative-free lubricant eye drops had previously launched in Europe the January before.
September saw the release of Total30 monthly replacement Water Gradient contact lenses. According to Alcon, clinical evidence showed the lenses “feel like nothing” even on day 30 due to the proprietary Water Gradient material that approaches 100% water at the surface. Biomimetic Celligent technology uses a unique lens chemistry to resist bacteria and lipid deposits, with an inherently lubricious surface as soft as the human cornea.
The company also shook up some of its executive committee last year. Former President, International, Ian Bell was named president of global business and innovation, replacing the departing Michael Onuscheck. Senior VP of Operational Strategy and Chief Transformation Officer Raj Narayanan succeeded Bell as president, International. Senior VP and Chief Information Officer Sue-Jean Lin was appointed senior VP and chief information and transformation officer, adding oversight of Alcon’s transformation program to her remit. All of the executive changes took effect Sept. 1, 2020.
$8.20 Billion
Prior Fiscal: $6.76 Billion
Percentage Change: +21.3%
R&D Expenditure: $557M
Best FY21 Quarter: Q4 $2.13B
Latest Quarter: Q1 $2.17B
No. of Employees: 24,389
Global Headquarters: Geneva, Switzerland
KEY EXECUTIVES:
David J. Endicott, CEO
Tim Stonesifer, CFO
Franck Leveiller, SVP, Head Global R&D
Heather Attra, SVP, Global Head Quality and Regulatory Affairs
Ian Bell, President, Global Business & Innovation
Jeanette Bankes, President & GM, Global Surgical Franchise
Andy Pawson, President & GM, Global Vision Care Franchise
In November, eye care firm Alcon celebrated the near-end of its third year as a standalone business by proclaiming its intention to acquire Ivantis, developer and manufacturer of the novel minimally-invasive glaucoma surgery (MIGS) device, the Hydrus Microstent. Designed to reduce intraocular pressure in open-angle glaucoma patients in connection with cataract surgery, Ivantis launched Hydrus in the U.S. and it’s also currently approved and marketed in the U.K., Germany, Canada, Australia, and Singapore.
The microstent is implanted into the Schlemm’s canal to boost outflow, reducing eye pressure to treat mild to moderate glaucoma. The company highlighted that a five-year Horizon clinical study showed 65% of Hydrus patients remained medication-free at five years post-implant, with 60% reduction in risk of invasive secondary glaucoma surgeries compared to cataract surgery alone.
“Glaucoma is the second-largest cause of blindness after cataracts, impacting more than 75 million people globally, with significant unmet patient need. This transaction will allow us to add a uniquely effective product into our glaucoma portfolio around the world,” Alcon CEO David Endicott told the press when the $475 million deal was announced. “Our global commercial footprint and development capabilities make us well positioned to build on the success of Ivantis and help even more patients see brilliantly with Hydrus Microstent.”
The deal for Ivantis was completed at the beginning of this year. Alcon plans to pursue further standalone surgery indications for Hydrus in the U.S., with clinical trials underway.
In 2021, Alcon’s net sales rebounded from COVID-19, which stifled many medical device market sectors. The firm posted $8.2 billion in revenue, rising about 21% over the year prior. The growth was driven mainly by landmark product launches as well as strong commercial execution and underpinned by global markets recovering from COVID-19, according to the company’s annual report.
Sales in the U.S. captured 44% of Alcon’s revenue with $3.7 billion posted. International sales reached $4.6 billion last year, making up the remaining 56%.
The surgical franchise contributed $4.7 billion to sales, rising an impressive 27% over the prior year that was impacted by the COVID-19 pandemic. Within the business, implantables proceeds grew 35% to $1.52 billion due to market improvements and the ongoing adoption of advanced technology intraocular lenses (IOLs), which included the rollout of Vivity and continued demand for PanOptix.
Consumables revenue increased 15% to $2.39 billion primarily due to market improvements over the prior year. Equipment/other sales rose 25% to $793 million, driven by demand for cataract and refractive equipment as well as other refractive products.
The surgical business’s one major product launch came in the U.S. last January with the AcrySoft IQ Vivity, a non-diffractive extended depth of focus IOL to mitigate presbyopia for patients undergoing cataract surgery. The first-of-its-kind IOL—approved by the FDA in February 2020—stretches and shifts light without splitting it, delivering monofocal-quality distance with “excellent” intermediate and functional near vision. Vivity is also available in toric designs and bolsters Alcon’s portfolio of presbyopia-mitigating IOLs.
The vision care business accrued $3.52 billion, growing 15% over the previous year, which was affected by COVID-19. Contact lenses sales grew 16% with $2.14 billion, due to strong U.S. recovery and growth in silicone hydrogel contact lenses including Precision1, Precision1 for Astigmatism, and Dailies Total1. Ocular health sales expanded 14% to $1.38 billion as a result of the Pataday Extra strength launch, and sales of Simbrinza after the firm’s acquisition of the U.S. commercialization rights.
The franchise began last year with the U.S. launch of Precision1 for Astigmatism contact lenses in January. The daily disposable, silicone hydrogel contact lens designed for astigmatic patients was born from the firm’s Water Gradient Technology and features SmartSurface, a permanent, micro-thin layer of moisture that steps up from 51% water at the core to over 80% water at the outer surface, according to Alcon data. This supports a stable tear film for lasting performance.
The exclusive U.S. rights from Novartis to sell the Simbrinza ophthalmic eye drops were gained last April. The drops are used to reduce elevated intraocular pressure for open-angle glaucoma or ocular hypertension patients. Combined with Alcon’s existing over-the-counter eye drops, adding Simbrinza makes for a bolstered ophthalmic eye drop portfolio.
That same day Alcon launched its Systane hydration multi-dose, preservative-free lubricant eye drops for sensitive dry eyes. The new option helps patients with aqueous deficient dry eye, protecting against further irritation and relieving dryness. Systane complete preservative-free lubricant eye drops had previously launched in Europe the January before.
September saw the release of Total30 monthly replacement Water Gradient contact lenses. According to Alcon, clinical evidence showed the lenses “feel like nothing” even on day 30 due to the proprietary Water Gradient material that approaches 100% water at the surface. Biomimetic Celligent technology uses a unique lens chemistry to resist bacteria and lipid deposits, with an inherently lubricious surface as soft as the human cornea.
The company also shook up some of its executive committee last year. Former President, International, Ian Bell was named president of global business and innovation, replacing the departing Michael Onuscheck. Senior VP of Operational Strategy and Chief Transformation Officer Raj Narayanan succeeded Bell as president, International. Senior VP and Chief Information Officer Sue-Jean Lin was appointed senior VP and chief information and transformation officer, adding oversight of Alcon’s transformation program to her remit. All of the executive changes took effect Sept. 1, 2020.